Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Remarkable to me

The license revenue from those deals (and the other 8 or so) was $1.409M as shown under the PDS info. Unfortunately, PDS burned through ovee $2M for the quarter so the net lost in equity in PDS was half of the $600K plus loss.

I'd say the delay was either overly optimistic and that PTSC got outmaneuvered in settlement talks yet again, or a delay tactic. Hard to see otherwise at first glance. Maybe the SHM will reveal a better explanation, but I'm not holding my breath.

Share
New Message
Please login to post a reply